T he field of molecular imaging has witnessed tremendous expansion since the turn of the century. 1, 2 Among the various imaging techniques, positron emission tomography (PET) is one of the most clinically relevant modalities for molecular imaging applications since PET is highly sensitive and quantitative and has superb tissue penetration of signal. With the invention of clinical PET scanners in the 1970s 3, 4 and dedicated small animal PET scanners in the late 1990s, 5 there have been numerous studies over the last several decades about the development of PET tracers. These tracers can play diverse roles in the diagnosis, staging, prognosis, and treatment monitoring of various diseases such as cancer, cardiovascular diseases, and neurological disorders.
In this featured topic issue of Molecular Pharmaceutics, I have invited a number of scientists from many different countries that are at the forefront of PET imaging to provide a "snapshot" of the current state of the art in PET research. The 25 articles (2 review articles and 23 original research articles) cover virtually all major areas of PET research. For example, with regard to research subjects employed in these studies, they included cells (i.e., in vitro studies), mice, rats, dogs, nonhuman primates, and cancer patients, which cover the entire spectrum of translational research. From the perspective of diseases that were investigated, this issue covers cancer (with multiple organ origins), cardiovascular diseases, and neurological diseases, which are the three major areas of imaging research. In terms of the agents that were labeled for PET imaging applications, this featured topic issue spans a diverse array of molecularly specific agents such as small molecules, amino acid analogues, peptides, affibodies, antibody fragments (e.g., diabody and minibody), monoclonal antibodies (mAbs), and nanoparticles. Together, the manuscripts in this issue cover almost all major classes of agents that have been labeled for imaging studies (with the exception of aptamers and nanobodies).
In the remainder of this Editorial, I will briefly describe each article in this issue starting from the 2 review articles. As stated in the scope of the journal, "Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development." In the first review article of this issue, I have worked with several of my colleagues to review the current status of PET image-guided drug delivery, which holds tremendous potential to revolutionize patient care by in vivo assessment of drug biodistribution and accumulation at the target sites. This review primarily focuses on the recent developments in PET image-guided drug delivery and discusses the intriguing opportunities for future development.
In parallel with the development of agents that can be detected with PET, there has also been exciting and steady progress in instrumentation. For example, PET/CT was initially developed ∼15 years ago 6 and PET/MRI scanners have also become commercially available for several years. 7, 8 In the second review article of this issue, Dr. Tian and colleagues reviewed the various technical challenges of building a PET/ MRI scanner, summarized the state-of-the-art design principles of PET/MRI, and elaborated its clinical applications in oncology, neurology, and cardiology. Clearly, PET/MRI will not replace PET/CT, which has been indispensable in clinical patient management. However, because of the exquisite soft tissue contrast and lack of ionizing radiation for MRI, PET/ MRI imaging will certainly become more widely used in the clinic in various scenarios for which PET/CT may not be adequate or ideal. The next 23 research articles will be described in the order of the size of the agents/ligands that were labeled with PET isotopes: small molecules (4), amino acid analogues (2), peptides (9), affibodies (2), antibody fragments (1), mAbs (4), and nanoparticles (1).
■ RADIOLABELED SMALL MOLECULES
For small molecules which have short circulation half-lives in living subjects, the use of 11 C (t 1/2 : 20.4 min) and 18 F (t 1/2 : 109.8 min) is quite common. Dr. de Vries and colleagues prepared N-[
11 C]methyl-AMD3465 as a new PET tracer for imaging of the chemokine receptor CXCR4 in a rat glioma model, and in vitro/in vivo/ex vivo studies suggested CXCR4 -specific binding of the tracer. In the next article, Dr. Long and colleagues described the one-pot-multitracer synthesis of two new 18 F-based mitochondrial imaging agents, which can be prepared in the same reaction vial from one 18 F-labeled synthon in a fully automated system. Dr. Zhang and colleagues described one-pot 18 F-labeling of several new phosphonium cations for PET imaging of myocardial perfusion. These tracers were investigated in both rats and beagle dogs, which exhibited high-contrast heart images with rapid clearance from the normal organs. Upon further optimizing the chemical structure of the tracer to reduce bone uptake, future studies are warranted in preclinical myocardial infarction models.
One important step of clinical translation from mice to human is the investigation of imaging agents in non-human primates, which closely mimic human biology/physiology. In this regard, Dr. Vasdev and colleagues carried out a study of 
■ RADIOLABELED AMINO ACID ANALOGUES
Radiolabeled amino acid analogues have been a dynamic area of research for the development of molecular imaging agents, especially in cancer since tumor cells generally exhibit high metabolism and, hence, will take up more amino acid (analogues) than normal cells. 9 Dr. Ametamey and co-workers synthesized and evaluated several 18 F-labeled fluoroethoxy tryptophan analogues as potential cancer imaging agents. From a series of these analogues, they found that [
18 F]6-FEHTP exhibits the highest tumor-to-background ratio in a small cell lung cancer xenograft model. They concluded that [
18 F]6-FEHTP may be an alternative PET tracer for imaging the activity of a large amino acid transporter, comparable to the previously reported agents in the literature. In the next article, Dr. Kung and colleagues developed new analogues of glutamine for studying glutamine metabolism in cancer cells. PET imaging of rat tumor models showed tumor-specific uptake of [ 18 F](2S,4S)4-(3-fluoropropyl)glutamine with good tumor-tomuscle ratio, which warrants further investigation. Furthermore, they also discovered that tumor uptake and retention mechanisms of this new tracer could be significantly different from those of the previously reported glutamine-based PET tracers.
■ RADIOLABELED PEPTIDES
Radiolabeled peptides was one of the most dynamic research areas over the past decade, clearly evidenced by a total of 9 research articles on this topic in this featured topic issue, far outnumbering all other categories. Ga-DOTA-PP-F11 was the best among the nine tracers for imaging various types of tumors that overexpress cholecystokinin-2.
The next manuscript is this issue, contributed by Dr. Wang, Dr. Chen, and colleagues, described the successful synthesis and in vivo evaluation of a 64 Cu-labeled dimeric NGR peptide based on the sarcophagine cage for PET imaging of CD13 expression. Since the sarcophagine cage can also be used for labeling with various other isotopes, the approach used in this study may be applied to the development of other radiopharmaceuticals for cancer diagnosis and treatment.
■ RADIOLABELED AFFIBODIES
Two studies in this issue employed affibodies as the targeting ligands for PET tracer development. Dr. Cheng and colleagues compared two site-specifically 18 F-labeled affibodies for PET imaging of tumors that overexpress the epidermal growth factor receptor. Two strategies were adopted for 18 F-labeling of the affibody, which contains an N-terminal cysteine to enable sitespecific labeling. Although both tracers could be rapidly synthesized, in vivo studies indicated that Al 18 F-NOTA-Z EGFR:1907 has better in vivo performance than the other tracer. The other article on this topic was from Dr. Tolmachev and colleagues, who labeled a DOTA-conjugated affibody Z09195 with generator-produced 68 Ga for PET imaging of plateletderived growth factor receptor β. One of the well-recognized major concerns for affibody-based tracers is the extremely high renal uptake, >200 %ID/g in this case, which will need to be dramatically reduced before potential clinical translation. ■ RADIOLABELED ANTIBODY FRAGMENTS Engineered antibody fragments are attractive targeting ligands for PET tracer development, since they can offer faster targetspecific delivery than mAbs with rapid clearance from the blood and normal tissues (i.e., better pharmacokinetics and image contrast). 12, 13 In the only manuscript focused on radiolabeled antibody fragments in this issue, Dr. Lewis, Dr. Wu, and coworkers investigated the use of minibody (∼80 kDa) and cysteine-diabody (∼50 kDa) as PET imaging agents upon labeling with 89 Zr (t 1/2 : 78.4 h). Both antibody fragments bind to the prostate specific membrane antigen (PSMA), a transmembrane protein overexpressed in a variety of tumor types such as prostate cancer. With the goal to establish pharmacokinetics of these antibody fragments being superior to that of huJ591 (an intact anti-PSMA mAb with molecular weight of ∼150 kDa) while maintaining tumor avidity and specificity to achieve same day PET imaging, they found that both 89 Zr-labeled antibody fragments exhibited rapid tumor delineation and background clearance. It was concluded that both types of antibody fragments are viable faster alternatives to radiolabeled intact mAbs.
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■ RADIOLABELED mAbs
Four articles in this issue are focused on radiolabeling of intact mAbs, since generation of engineered antibody fragments is quite technically challenging (although enzyme digestion of intact mAbs may offer an alternative in some cases 14, 15 ). Dr. Li, Dr. Shan, and colleagues developed a novel probe based on a mAb h173 for PET imaging of Axl, which plays a critical role in tumorigenesis and metastasis of various tumor types. The tracer, 64 Cu-DOTA-h173, showed good Axl specificity in vitro and in vivo, which may potentially be used in a future clinical setting for staging of Axl-positive tumors and various other aspects of cancer patient management. Next, Dr. Anderson and colleagues conjugated two recently developed cross-bridged macrocyclic chelators (CB-TE1A1P and CB-TE1K1P) to cetuximab via different chemical linkages: conventional NHSaided coupling or click chemistry. They concluded that both agents showed improved in vivo performance over 64 Cu-DOTA-cetuximab, a tracer reported many years ago. 16 In addition, they suggested that these bioconjugation strategies provided opportunities for using click chemistry to stably label a wide variety of heat-sensitive biological molecules (e.g., mAbs and antibody fragments) with 64 Cu. In the next article, Dr. Lapi and colleagues labeled pertuzumab, a mAb that binds to the human epidermal growth factor receptor 2 (HER2), and carried out a series of in vitro and in vivo studies. Interestingly, pertuzumab binds to an HER2 binding site that is distinct from that of trastuzumab, another anti-HER2 mAb, and its affinity is enhanced when trastuzumab is present. Through a very well-designed study, they found that 89 Zr-pertuzumab PET could detect HER2 expression selectively in breast cancer xenograft models with increased tumor uptake in the presence of trastuzumab, making 89 Zr-pertuzumab a promising tracer for PET imaging of HER2-positive breast cancer undergoing trastuzumab therapy to enhance the sensitivity of HER2 detection in vivo. In the next article, Dr. Jagoda and co-workers labeled a therapeutic antitumor endothelial marker 8 (TEM8) mAb with 89 Zr and evaluated its properties both in vitro and in vivo. The tracer showed TEM8 specificity in vitro and in vivo, and enabled sufficient tumor delineation with noninvasive PET imaging.
■ RADIOLABELED NANOPARTICLES
Nanoparticles can be used for image-guided drug delivery, 17, 18 as discussed in detail in the first review article of this featured topic issue. In the last research article of this issue, we completed the circle and reported PET/optical imaging with antibody fragment-conjugated, dual-labeled mesoporous silica nanoparticles (MSN). 64 Cu, 800CW (a near-infrared fluorescent [NIRF] dye), and TRC105 Fab (which binds to CD105, overexpressed on tumor neovasculature 19 ) were conjugated to the surface of MSN to yield a dual-labeled MSN for in vivo targeted PET/NIRF imaging of the tumor vasculature. Vascular CD105 targeting led to ∼2-fold enhancement of tumor accumulation over passive targeting alone, warranting future investigation of MSN and/or related nanoplatfoms (e.g., hollow mesoporous silica nanoparticles 20, 21 ) for PET-image guided drug delivery.
The 25 articles in this featured topic issue originated from many countries, including the United States, China, The Netherlands, United Kingdom, Switzerland, Germany, and Sweden. I am deeply grateful to all the contributors for their tremendous effort and time devoted to the outstanding articles in this issue. With 23 research articles contributed by internationally recognized leaders of the field that cover virtually all major classes of targeting ligands, most commonly used PET isotopes, and all major areas of imaging research, this issue provided a timely snapshot of the current state of the art of PET imaging research. I sincerely hope this featured topic issue will be able to attract young talents into this vibrant research arena with an extremely exciting future. Meanwhile, I look forward to seeing rapid translation of the latest and greatest PET tracers into clinical investigation, which will undoubtedly play indispensable and multifaceted roles in the realization of personalized medicine, precision medicine, and the emerging concept of theransotics (i.e., diagnostics + therapy).
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